Rite Aid Corporation RAD has reported Q2 FY22 adjusted net loss of ($0.41) per share, compared to an income of $0.25 a year ago, but beating the consensus of $(0.48).
Earnings: Revenues increased 2.2% Y/Y to $6.11 billion, missing the estimate of $6.21 billion. The sales growth was driven by the Retail Pharmacy Segment, partially offset by a decline at the Pharmacy Services Segment.
Retail Pharmacy Segment revenues increased 6.5% Y/Y to $4.28 billion, driven by an increase in same-store sales and the inclusion of Bartell's results. Same-store sales increased 2.6%, consisting of a 5% increase in pharmacy sales and a 2.8% decrease in front-end sales.
The number of prescriptions filled in the same stores increased 7.1%. In addition to the benefit from COVID-19 vaccinations, other acute prescriptions increased 1.5%, and maintenance prescriptions increased 2.4% on the same-store basis.
The total store count at the end of the second quarter was 2,501.
Pharmacy Services Segment revenues declined 6.9% to $1.9 billion, primarily due to a decrease in membership in the PBM business and a reduction in Elixir Insurance membership.
Guidance: Revenues guidance for FY22 remains unchanged at $25.1 billion - $25.5 billion (consensus $25.13 billion). But, the Company expects Pharmacy Services Segment revenue of $7.7 billion - $7.8 billion, down from the prior outlook of $7.9 billion - $8.0 billion.
The Company expects a wider net loss for FY22 of $221 million - $197 million, against $175 million - $138 million expected earlier. Adjusted EPS loss is expected to be $(0.90) - $(0.53) (compared to $(0.79) - $(0.24) expected previously). Adjusted EBITDA is expected to be $460 million - $500 million, slightly better than prior guidance of $440 million - $480 million.
Read Next: CVS, Walgreens, Rite Aid Shares Fall On Report Of Potential Amazon Entry Into Retail Pharmacy.
Price Action: RAD stock is down 7.35% at $14.14 during the market session on the last check Thursday.
Photo by Ildar Sagdejev via Wikimedia
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.